.webp)
Hair loss treatments are evolving, offering new options for faster results and fewer side effects. If you're dealing with androgenic alopecia (male or female pattern hair loss), here’s what you need to know:
- PP405: A hormone-free topical treatment that reactivates dormant hair follicle stem cells. Early trials show a 20%+ increase in hair density for 31% of users within 8 weeks. Phase 3 trials are set for 2026.
- ET 02: Targets both hair loss and graying by rejuvenating stem cells and melanocytes. Initial studies report thicker, denser hair in just 4 months. Still in early clinical stages.
- Breezula (clascoterone): A topical DHT blocker that prevents hair follicle shrinkage without systemic side effects. Clinical trials show 12.7 additional hairs per cm² after 12 months.
- Plant-Based DHT Blockers: Options like saw palmetto and green tea extract offer natural alternatives for early-stage hair loss. Results vary, and evidence is limited.
- Topical Spironolactone: Available via telehealth platforms like Oana Health for $43/month. Especially effective for women with PCOS-related hair loss, offering localized anti-androgen benefits.
Key takeaway: These topical treatments bring new hope for addressing hair loss with less risk than oral medications. While some are already available, others like PP405 and ET 02 are still undergoing trials. Women with PCOS, in particular, may benefit from targeted options like spironolactone.
Read on for a deeper look at how these treatments work, their safety profiles, and what to expect in terms of availability and cost.
NEW Hair Loss Drug to Cure BALDNESS? | PP405
1. PP405
PP405 is a new, hormone-free treatment designed to reactivate dormant hair follicle stem cells. Instead of relying on hormonal pathways, it tackles the root cause of hair loss, marking a fresh approach to managing androgenic alopecia.
How It Works
PP405 works by targeting the mitochondrial pyruvate carrier (MPC), a protein involved in cellular metabolism. By inhibiting MPC, the treatment reactivates dormant hair follicle stem cells in areas experiencing hair loss. This mechanism directly addresses the key pathway responsible for hair growth, which explains the positive outcomes seen in early clinical trials.
Clinical Studies
In a Phase 2a clinical trial, 78 participants with androgenic alopecia were studied. The trial was randomized, double-blind, and vehicle-controlled. Among men with more advanced hair loss, 31% experienced a more than 20% increase in hair density within just eight weeks of using PP405. This improvement was not only significant but also faster than results typically seen with traditional treatments. Meanwhile, the placebo group showed no change.
"A well-tolerated, topically delivered therapy showing measurable biological activity this early is rare and could reshape clinical approaches to hair growth", stated Dr. Arash Mostaghimi, vice chair of Clinical Trials and Innovation at Brigham and Women's Hospital.
Safety and Tolerance
PP405’s localized action contributes to its strong safety profile. The treatment showed no systemic absorption and no major adverse events during trials. Side effects were minimal and limited to the application site, reducing the risks often associated with oral medications.
Potential for Women and PCOS Patients
The trial included both men and women, suggesting that PP405 could be effective for a wide range of individuals. While specific data on women with PCOS-related hair loss isn’t available yet, the hormone-free nature of the treatment makes it a promising option for these patients, as it avoids altering androgen pathways.
Current Status and Future Plans
PP405 is still in the investigational phase and hasn’t been released commercially in the United States. Phase 3 trials are scheduled for 2026 to further assess its safety and effectiveness in larger, longer-term studies. Pricing details will be determined after regulatory approval. This therapy represents a growing trend toward regenerative, topical solutions for hair loss.
2. ET 02
ET 02 is a topical therapy under development by Eirion Therapeutics, designed to tackle hair loss and graying by rejuvenating stem cells and activating melanocytes for hair pigment restoration and growth.
How It Works
ET 02 works by reactivating dormant hair follicle stem cells and stimulating melanocytes. This dual action helps promote hair regrowth while restoring natural hair color.
Clinical Insights
ET 02 has completed Phase 1 clinical trials, with Phase 2 trials slated to begin in 2025. Early results are promising - participants reported noticeable improvements in hair thickness, growth speed, and overall hair density after just four months of daily use. Dr. Jerry Shapiro, a leading expert from NYU Grossman School of Medicine, has been involved in the clinical evaluation, underscoring the potential of this therapy.
Safety Highlights
Preliminary findings suggest ET 02 has fewer side effects compared to older hormonal treatments, with no reports of sexual dysfunction. While long-term safety data is still pending, early results point to a favorable safety profile, making it a potential option for women, including those with PCOS-related hair loss.
Potential for Women and PCOS Patients
ET 02’s non-hormonal approach could be a game-changer for women, especially those struggling with PCOS-related hair loss. Traditional anti-androgen therapies often come with hormonal side effects, but ET 02’s focus on stem cell rejuvenation offers a different path. Although specific studies for these groups are not yet available, the therapy’s mechanism provides hope for a more targeted and less invasive solution.
Current Availability and Future Costs
ET 02 is still in the investigational stage and hasn’t received FDA approval. It’s currently accessible only through clinical trials in the United States. Pricing and insurance coverage details remain unknown, but future costs will likely depend on factors like production and reimbursement policies. Those interested in trying ET 02 should monitor updates from Eirion Therapeutics and explore clinical trial opportunities for enrollment.
3. Topical DHT Blockers (e.g., Breezula)
Topical DHT blockers are gaining attention as a way to combat androgenic alopecia by focusing directly on the effects of dihydrotestosterone (DHT) at the scalp. Among these, Breezula (clascoterone) stands out as the first topical androgen receptor inhibitor specifically created to address hair loss.
How It Works
Breezula works by targeting DHT at the scalp level. It blocks DHT from binding to receptors in hair follicles, which helps prevent the miniaturization of these follicles - a key factor in hair loss. Unlike oral DHT blockers that reduce DHT production throughout the body, Breezula’s localized application significantly reduces the likelihood of systemic side effects. This makes it a complementary option to other topical treatments discussed earlier.
Evidence from Clinical Trials
Clinical trials have shown promising results for Breezula. In Phase 2 studies, a 7.5% solution led to a noticeable improvement, with up to 12.7 additional hairs per square centimeter after 12 months of use. These results highlight its potential as an effective treatment for male pattern baldness.
Comparing Safety Profiles
To better understand how Breezula stacks up, here’s a comparison of oral and topical DHT blockers:
| Feature | Oral DHT Blockers | Topical DHT Blockers (Breezula) |
|---|---|---|
| Systemic Side Effects | Common (e.g., reduced libido) | Rare (mostly local irritation) |
| Mechanism | Reduces DHT production body-wide | Blocks DHT action directly on the scalp |
| Most Common Side Effect | Sexual dysfunction | Mild skin irritation |
Breezula’s safety profile is encouraging, with the most frequent side effect being mild skin irritation at the application site. Importantly, no hormonal imbalances or systemic side effects have been reported in clinical trials.
Potential for Female and PCOS Patients
Early studies in women suggest Breezula could be a suitable option for hair loss related to PCOS (polycystic ovary syndrome). Its localized action minimizes systemic hormonal impact, making it a safer alternative for addressing hormone-driven hair loss in women, similar to the benefits observed with treatments like PP405 and ET 02.
Availability and Cost Expectations
Breezula is still undergoing clinical trials and regulatory review in the United States. If approved by the FDA, it’s expected to be available by prescription starting in late 2025. Once launched, it will provide a targeted treatment for hair loss, addressing hormonal causes while minimizing systemic risks.
sbb-itb-6dba428
4. Plant-Based and Natural DHT Blockers
For those looking for gentler options to address androgenic alopecia, plant-based DHT blockers provide a natural alternative. These solutions are gaining attention as a less invasive approach to managing hair loss.
How They Work
Plant-based DHT blockers target the enzyme 5-alpha-reductase, which is responsible for converting testosterone into DHT, the hormone linked to hair follicle shrinkage. Ingredients like saw palmetto, pumpkin seed oil, green tea extract (EGCG), and tea tree oil are commonly used in these treatments. By reducing DHT levels, these blockers help prevent follicle miniaturization and may soothe scalp inflammation. They are typically applied directly to the scalp in topical formulations, allowing for targeted action.
What the Research Says
Preliminary studies and anecdotal reports hint at promising results. For example, one case series observed modest hair regrowth and reduced shedding in men and women who used a topical saw palmetto serum for 24 weeks. Side effects were minimal, but it’s important to note that larger, more rigorous clinical trials are needed to fully validate these findings.
Are They Safe?
Generally, plant-based DHT blockers applied topically are well tolerated. Some users with sensitive skin might experience mild irritation or allergic reactions, but systemic side effects are rare due to limited absorption into the bloodstream.
A Good Option for Women and PCOS
These natural treatments are particularly appealing for women, including those dealing with PCOS-related hair loss. Because they don’t involve systemic hormonal changes like oral therapies, they’re considered a safer choice. Their gentle action makes them suitable for early-stage hair loss or as part of a broader management plan for female pattern hair loss.
Cost and Accessibility
In the United States, you can find plant-based topical DHT blockers in most pharmacies, health stores, and online marketplaces. Prices typically range from $20 to $60 per bottle, depending on the brand, ingredient quality, and concentration. Experts suggest starting treatment early and applying it daily for several months to evaluate its effectiveness. The combination of affordability and ease of access makes these products a practical option for many people seeking to manage hair loss.
5. Oana Health Topical Spironolactone
Oana Health has introduced a prescription-based topical spironolactone designed to address androgen-driven hair loss in women, particularly those with PCOS. Priced at $43 per month, this treatment reflects the growing shift toward localized and targeted solutions for hair loss.
How It Works
Topical spironolactone works by blocking androgen receptors in the scalp tissue. This reduces the impact of DHT (dihydrotestosterone) on hair follicles, helping to prevent follicle shrinkage and hair loss. Because it's applied directly to the scalp, it minimizes systemic absorption, focusing its effects where they’re needed most.
Evidence and Effectiveness
Although research is still limited to smaller trials and case reports, the available data suggests that topical spironolactone can improve hair density and slow hair loss. Many dermatology experts agree it’s both effective and well-tolerated, offering a promising option for patients who may not be suitable for oral anti-androgen treatments.
Safety and Side Effects
One of the key advantages of topical spironolactone is its safety profile. Most side effects are mild and localized, such as scalp irritation, redness, or itching. Unlike oral formulations, it avoids systemic side effects like hormonal imbalances or electrolyte disturbances, making it a safer choice for long-term use.
Ideal for Women with PCOS
Women with PCOS often face hair loss driven by elevated androgen levels. Oral anti-androgens can sometimes cause unwanted side effects, but the localized action of topical spironolactone makes it a better fit, especially for women of reproductive age who need a long-term treatment option.
Accessibility and Cost
Oana Health provides an easy and affordable way to access topical spironolactone through its telehealth platform, available across the United States. Patients can consult with licensed providers online, receive a tailored prescription, and have the medication delivered directly to their doorstep with free shipping. Results typically become noticeable after 6–12 months of consistent use, with regular follow-ups to monitor progress. At $43 per month, it’s a convenient and science-based solution for women dealing with PCOS-related hair loss.
Benefits and Drawbacks
Each treatment discussed earlier brings its own set of strengths and limitations, which must be carefully considered based on individual needs and timelines. Here's a closer look at the advantages and challenges of these innovations.
PP405 takes a groundbreaking approach to tackling hair loss by reactivating dormant hair follicle stem cells rather than targeting hormones. This makes it a promising option for those who haven’t seen results with traditional treatments. It offers rapid improvements in hair density with minimal side effects, as it doesn’t involve systemic absorption. However, its biggest limitation is availability - PP405 is still in clinical trials, with Phase 3 studies planned for 2026, meaning it won’t be commercially accessible for several years.
ET 02 stands out for addressing both hair thinning and graying at the same time. Its non-hormonal mechanism makes it a suitable choice for women and individuals with PCOS who may struggle with hormone-based treatments. Early results are encouraging, and no serious side effects have been reported. However, like PP405, ET 02 is still in the investigational phase, so it’s currently only available through clinical trials.
Topical DHT Blockers, such as Breezula, offer a targeted way to block scalp DHT without the systemic side effects often associated with oral treatments. While this approach can significantly boost hair counts, some users may experience local scalp irritation. Availability is another challenge, as many formulations are still awaiting broader regulatory approval. Costs for these treatments typically range from $30 to $100 per month with a prescription.
Plant-Based and Natural DHT Blockers are a more accessible option, widely available over-the-counter at prices ranging from $20 to $60 per month. These treatments appeal to those looking for gentler, early-stage solutions. However, the clinical evidence supporting their effectiveness is limited and mixed, and results can be unpredictable compared to prescription therapies.
Oana Health's Topical Spironolactone offers a targeted solution for PCOS-related hair loss at a reasonable price of about $43 per month. This treatment delivers anti-androgen benefits without the systemic risks linked to oral medications. Its telehealth model improves accessibility, offering personalized treatment plans and direct-to-home delivery. While smaller studies and case reports support its use, it lacks robust data for male patients and may cause local scalp irritation.
The table below summarizes these treatments across key factors:
| Treatment | Mechanism of Action | Clinical Evidence | Safety Profile | Suitability for Female/PCOS Patients | Availability and Cost |
|---|---|---|---|---|---|
| PP405 | Reactivates follicle stem cells | Phase 2a: 31% saw >20% increase in density at 8 weeks | Well tolerated; no systemic absorption | Suitable for both men and women | In trials; commercial release pending |
| ET 02 | Restores stem cell and pigment function | Phase 1: 6× thicker hairs, 10% wider shafts in 5 weeks | No serious side effects; non-hormonal | Suitable for both men and women | Investigational only |
| Topical DHT Blockers | Inhibit scalp DHT locally | Significant hair count increases at 24 weeks | Local irritation possible; fewer systemic effects | Varies by formulation | Limited availability; ~$30–$100/month |
| Plant-Based DHT Blockers | Natural DHT inhibition via botanical extracts | Limited and mixed evidence from small studies | Generally well tolerated; possible skin irritation | Often marketed for women | Widely available OTC; ~$20–$60/month |
| Topical Spironolactone | Local anti-androgen that blocks androgen receptors | Case series and small trials indicate efficacy | Minimal systemic risk; possible local irritation | Especially suitable for PCOS patients | Prescription/telehealth; ~$40–$120/month |
Overall, these treatments cater to individuals seeking safer alternatives to oral medications, with topical solutions reducing systemic exposure while still delivering therapeutic results. Women with PCOS, in particular, have a range of strong options - from the hormone-neutral approaches of PP405 and ET 02 to the targeted anti-androgen benefits of topical spironolactone through platforms like Oana Health.
Costs vary widely, from affordable over-the-counter options to prescription treatments requiring ongoing medical oversight. Patients must balance availability with potential effectiveness, keeping in mind that some of the most promising treatments are still years away from commercial release.
Conclusion
The treatment landscape for androgenic alopecia is evolving, offering more precise and effective options. Emerging therapies like PP405, ET 02, and targeted anti-androgens are expanding the range of choices available, complementing traditional approaches and addressing unmet needs.
PP405 shows promise in increasing hair density by reactivating dormant hair follicle stem cells. While initial results are encouraging, its commercial availability depends on the completion of further clinical trials.
Topical spironolactone, particularly beneficial for PCOS-related hair loss, provides a tailored solution. Platforms like Oana Health make it easier for patients to access personalized, prescription-based treatments through telehealth services.
ET 02 offers a dual-action approach, addressing both hair thinning and graying. Early results highlight improvements in hair thickness and shaft width within just five weeks. Dr. Jerry Shapiro of NYU Grossman School of Medicine has referred to ET 02 as:
"an anti-aging agent for hair follicles"
However, like PP405, ET 02 is still undergoing clinical trials.
Telehealth platforms are revolutionizing access to these advancements, enabling online consultations, customized treatment plans, and direct delivery of prescription therapies. For patients unable to tolerate or benefit from oral medications, these topical alternatives offer new hope. Women with PCOS may find targeted relief with topical spironolactone, while those seeking non-hormonal solutions should keep an eye on the progress of PP405 and ET 02. With their innovative mechanisms, favorable safety profiles, and the convenience of telehealth, these treatments are making androgenic alopecia management more accessible and personalized. Continued research and a patient-first approach will be key to advancing outcomes in this dynamic field.
FAQs
How do PP405 and ET02 differ in their mechanisms and effectiveness for treating hair loss?
PP405 and ET02 are two topical treatments designed to tackle androgenic alopecia, but they work in distinct ways to address hair loss. PP405 boosts blood flow to the hair follicles and encourages growth by targeting specific growth factors. Meanwhile, ET02 works by minimizing the effects of dihydrotestosterone (DHT) - a hormone known to shrink hair follicles - helping to slow down hair loss and support the growth of thicker, healthier hair.
Although both treatments aim to enhance hair density and quality, the results can differ based on factors like the extent of hair loss and how your scalp responds to the treatment. To find the best option for your needs, it’s important to consult a licensed medical professional.
How do topical DHT blockers like Breezula compare to plant-based alternatives in terms of effectiveness and safety?
Topical DHT blockers, like Breezula, aim to counteract the effects of dihydrotestosterone (DHT) - a hormone closely tied to androgenic alopecia. These treatments often use lab-created compounds designed to target hair follicles directly, reducing DHT’s activity.
On the other hand, plant-based DHT blockers lean on natural ingredients such as saw palmetto or pumpkin seed oil. While these may offer a gentler approach, their impact tends to be milder compared to synthetic options.
Synthetic treatments like Breezula are currently undergoing clinical trials and show encouraging results. However, plant-based alternatives are often favored for their potentially lower risk of side effects. That said, effectiveness can vary significantly based on the individual and the product’s formulation. For the best results, it’s always wise to consult a healthcare professional to find the option that works for you.
How can topical spironolactone help women with PCOS-related hair loss?
Topical spironolactone can be a game-changer for women dealing with PCOS-related hair loss. It addresses the hormonal imbalance tied to the condition by blocking androgens (male hormones) from affecting hair follicles. This process may help reduce hair thinning and encourage healthier hair growth over time.
What sets topical spironolactone apart from oral treatments is its localized action. It works directly where it's applied, significantly lowering the chances of systemic side effects. For women seeking a focused, gentle approach to tackle PCOS-driven hair loss, this option can be an effective and well-tolerated choice.
